Share on LinkedInShare on LinkedIn

ARTICLE · 09 NOVEMBER 2026

Recent PFAS Updates: FDA And Federal Court Demand Reasoned Basis For PFAS Rules

Dechert
Dechert
Contributor
Dechert

Dechert

Dechert helps business leaders lead For more than 150 years, we’ve advised the innovators who move...

View firm profile
Explore more from Dechert

This monthly newsletter examines critical developments in product liability and mass tort litigation, including FDA guidance on PFAS in medical devices, state-level AI regulation in legal practice...

United StatesLitigation, Mediation & Arbitration

Key Takeaways

  • The FDA continues to provide medical device manufacturers with agency-backed support for fluoropolymer use, underscoring that those PFAS compounds are well studied and that there is no evidence of harm from their use in medical devices. 
  • Similarly, a federal court preliminarily enjoined a New Mexico PFAS-labeling requirement because it lacked a rational connection to promoting public health goals, suggesting that First Amendment protections for commercial speech remain a meaningful check on PFAS-labeling mandates.

Two recent developments are noteworthy at the intersection of per- and polyfluoroalkyl substances (“PFAS”) and products liability. First, the FDA updated public statements about PFAS in medical devices on its webpage. As previously covered in Re:Torts, the FDA recognizes that fluoropolymers, a particular type of PFAS comprised of large molecules, are essential for use in many medical devices. The FDA reaffirmed that “PFAS in the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from